gastric juice protein comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Trump, an anonymous jury found Trump civilly liable for sexual abuse and defamation, and ordered him to pay Carroll $5 million in damages. In a related case brought by Carroll against Trump, a jury awarded Carroll $83.3 million. As of April 2025, appeals were ongoing in both cases. In September 2023, Trump was found civilly liable for financial fraud in New York v. Trump. In February 2024, he was ordered to pay a $354.8 million fine, together with approximately $100 million in interest. As of January 29, 2025, an appeal was ongoing. Trump made efforts to delay his trials until after the 2024 election. On July 1, 2024, the Supreme Court delivered a 6–3 decision in Trump v. United States, ruling that Trump had absolute immunity for acts he committed as president within his core constitutional purview, at least presumptive immunity for official acts within the outer perimeter of his official responsibility, and no immunity for unofficial acts.
=== EC 1.3.99 With unknown physiological acceptors === EC 1.3.99.1: The activity is included in EC 1.3.5.1, succinate dehydrogenase (quinone) EC 1.3.99.2: Now EC 1.3.8.1, butyryl-CoA dehydrogenase. EC 1.3.99.3: now EC 1.3.8.7, medium-chain acyl-CoA dehydrogenase, EC 1.3.8.8, long-chain acyl-CoA dehydrogenase and EC 1.3.8.9, very-long-chain acyl-CoA dehydrogenase EC 1.3.99.4: 3-oxosteroid 1-dehydrogenase EC 1.3.99.5: 3-oxo-5α-steroid 4-dehydrogenase (acceptor) EC 1.3.99.6: 3-oxo-5β-steroid 4-dehydrogenase EC 1.3.99.7: Now EC 1.3.8.6, glutaryl-CoA dehydrogenase EC 1.3.99.8: 2-furoyl-CoA dehydrogenase EC 1.3.99.9: Now EC 1.21.99.1, β-cyclopiazonate dehydrogenase EC 1.3.99.10: Now EC 1.3.8.4, isovaleryl-CoA dehydrogenase EC 1.3.99.11: transferred to EC 1.3.5.2, dihydroorotate dehydrogenase EC 1.3.99.12: Now classified as EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.99.13: Now EC 1.3.8.8, long-chain-acyl-CoA dehydrogenase EC 1.3.99.14: cyclohexanone dehydrogenase EC 1.3.99.15: Now EC 1.3.7.8 EC 1.3.99.16: isoquinoline 1-oxidoreductase EC 1.3.99.17: quinoline 2-oxidoreductase EC 1.3.99.18: quinaldate 4-oxidoreductase EC 1.3.99.19: quinoline-4-carboxylate 2-oxidoreductase EC 1.3.99.20: Now EC 1.3.7.9, 4-hydroxybenzoyl-CoA reductase EC 1.3.99.21: Now EC 1.3.8.3, (R)-benzylsuccinyl-CoA dehydrogenase EC 1.3.99.22: Now EC 1.3.98.3, coproporphyrinogen dehydrogenase EC 1.3.99.23: all-trans-retinol 13,14-reductase EC 1.3.99.24: Now EC 1.3.8.16, 2-amino-4-deoxychorismate dehydrogenase EC 1.3.99.25: carvone reductase EC 1.3.99.26: all-trans-ζ-carotene desaturase EC 1.3.99.27: 1-hydroxycarotenoid 3,4-desaturase EC 1.3.99.28: phytoene desaturase (neurosporene-forming) EC 1.3.99.29: phytoene desaturase (zeta-carotene-forming) EC 1.3.99.30: phytoene desaturase (3,4-didehydrolycopene-forming) EC 1.3.99.31: phytoene desaturase (lycopene-forming) EC 1.3.99.32: glutaryl-CoA dehydrogenase (non-decarboxylating) EC 1.3.99.33: urocanate reductase EC 1.3.99.34: Now classified as EC 1.3.7.11, 2,3-bis-O-geranylgeranyl-sn-glycero-phospholipid reductase EC 1.3.99.35: Now EC 1.3.7.15, chlorophyllide a reductase * EC 1.3.99.36: cypemycin cysteine dehydrogenase (decarboxylating) EC 1.3.99.37: 1-hydroxy-2-isopentenylcarotenoid 3,4-desaturase EC 1.3.99.38: menaquinone-9 β-reductase EC 1.3.99.39: carotenoid φ-ring synthase EC 1.3.99.40: carotenoid χ-ring synthase
coli, which became better at surviving a mixture of animal antimicrobial peptides in vitro and more effective at killing infected caterpillars. Not all resistance to colistin and some other antibiotics is due to the presence of resistance genes. Heteroresistance, the phenomenon wherein apparently genetically identical microbes exhibit a range of resistance to an antibiotic, has been observed in some species of Enterobacter since at least 2016 and was observed in some strains of Klebsiella pneumoniae in 2017–2018. In some cases this phenomenon has significant clinical consequences.
Sources: en.wikipedia.org
1993/2257) Bath Mental Health Care National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2258) Wiltshire Health Care National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2259) North Mersey Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2260) Bath and West Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2261) Royal United Hospital, Bath, National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2262) Weybourne Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2263) King's Lynn and Wisbech Hospitals National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/2264) Hydrocarbon Oil (Amendment) Regulations 1993 (S.I. 1993/2267) Local Government Act 1988 (Defined Activities) (Exemption) (Horsham District Council and Worthing Borough Council) Order 1993 (S.I. 1993/2269) Finance (No. 2) Act 1992 (Commencement No. 6 and Transitional Provisions and Savings) Order 1993 (S.I. 1993/2272) Income Tax (Employments) (Amendment) Regulations 1993 (S.I. 1993/2276) Smoke Control Areas (Exempted Fireplaces) Order 1993 (S.I. 1993/2277) Sea Fish Licensing (Variation) (No. 2) Order 1993 (S.I. 1993/2291) Friendly Societies (Proxy Voting) Regulations 1993 (S.I. 1993/2294) Commissioners for Oaths (Fees) Order 1993 (S.I. 1993/2297) Commissioners for Oaths (Authorised Persons) (Fees) Order 1993 (S.I.
=== Safety === Like for other radioactive imaging agents in medicine, the applied amounts of radioactivity are so low that radiation-related adverse effects are very unlikely to occur, and have not been observed in practice. Consistent with the "tracer principle", the amount of pharmacologically active compound injected to a patient in the course of such an examination is extremely low. Adverse events, such as toxicity or allergic reactions, are thus highly improbable. No adverse or clinically detectable pharmacologic effects were observed following intravenous administration of 68Ga-Trivehexin when administered to cancer patients, and there were no significant changes in vital signs, laboratory study results, or electrocardiograms. In a study involving healthy volunteers, researchers again reported no adverse or clinically detectable pharmacologic effects and no significant changes in vital signs.
==== CLIP release ==== In order to ensure that no false peptides bind to an MHC class II molecule, the peptide-binding groove is occupied by a protein called CLIP. Once a proper peptide is encountered, HLA-DM catalyzes the exchange of CLIP for an antigen peptide. Often, this peptide is retrieved directly from the B cell receptor which internalized it. Through expulsion of CLIP at the proper time, HLA-DM ensures that the correct antigen can bind to MHC molecules and prevent either from degrading.
Sources: en.wikipedia.org
=== Critical reviews === The first episode of the series received positive reviews with Rotten Tomatoes giving it a 100% rating with 9 reviews from critics. Metacritic gave the series a 77% rating based on six reviews. Ben Travers of IndieWire wrote, "Its sense of humor may call to mind Conan O'Brien's absurdist Late Night work, and the visual style may hearken back to Johnny Carson's era, but John Mulaney isn't trying to make another late-night talk show. He's trying to make his". Alison Herman of Variety described the show as being "consistently delightful chaos" adding, "Part of what made Everybody's in LA so exciting was in how it took the cultural decline of the talk show as an opportunity. Rather than subjecting itself to the endless grind of daily headlines or relying on stars' promotional schedules to book guests, the show would embrace the niche fascination its genre was already trending toward — treating 'talk show' like an aesthetic to be tried on and toyed with, not a set of expectations to be met."
1993/1626) Castle Vale Housing Action Trust (Area and Constitution) Order 1993 (S.I. 1993/1634) Gipsy Encampments (Borough of Surrey Heath) Order 1993 (S.I. 1993/1635) Tower Hamlets Housing Action Trust (Area and Constitution) Order 1993 (S.I. 1993/1636) Value Added Tax (General) (Amendment) (No. 5) Regulations 1993 (S.I. 1993/1639) Reconstitution of the Witham First District Internal Drainage Board Order 1993 (S.I. 1993/1640) Import (Plant Health Fees) (England and Wales) Order 1993 (S.I. 1993/1641) Plant Passport (Plant Health Fees) (England and Wales) Regulations 1993 (S.I. 1993/1642) Environmental Protection (Controls on Injurious Substances) (No. 2) Regulations 1993 (S.I. 1993/1643) Alcan Aluminium UK Ltd. (Rateable Values) (Scotland) Order 1993 (S.I. 1993/1644) Forth Ports plc (Rateable Values) (Scotland) Order 1993 (S.I. 1993/1645) Caledonian MacBrayne Limited (Rateable Values) (Scotland) Order 1993 (S.I. 1993/1646) Tunbridge Wells and Eridge Light Railway Order 1993 (S.I. 1993/1651) Asylum and Immigration Appeals Act 1993 (Commencement and Transitional Provisions) Order 1993 (S.I. 1993/1655) Immigration (Restricted Right of Appeal against Deportation) (Exemption) Order 1993 (S.I. 1993/1656) Immigration (Variation of Leave) (Amendment) Order 1993 (S.I. 1993/1657) Extraction Solvents in Food Regulations 1993 (S.I. 1993/1658) Education (Assisted Places) (Scotland) Amendment Regulations 1993 (S.I. 1993/1659) St Mary's Music School (Aided Places) Amendment Regulations 1993 (S.I. 1993/1660) Asylum Appeals (Procedure) Rules 1993 (S.I.
=== Side effects === No known toxicity is associated with high oral doses of the vitamin K1 or vitamin K2 forms of vitamin K, so regulatory agencies from US, Japan and European Union concur that no tolerable upper intake levels needs to be set. However, vitamin K1 has been associated with severe adverse reactions such as bronchospasm and cardiac arrest when given intravenously. The reaction is described as a nonimmune-mediated anaphylactoid reaction, with incidence of 3 per 10,000 treatments. The majority of reactions occurred when polyoxyethylated castor oil was used as the solubilizing agent.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.